Department of Gastroenterology, West China Hospital of Sichuan University, Chengdu, China.
Department of Immunology, University of Toronto, Toronto, ON, Canada.
Curr Neuropharmacol. 2024;22(14):2314-2329. doi: 10.2174/1570159X22666240308090741.
Alzheimer's disease (AD) is the most prevalent type of dementia, but its etiopathogenesis is not yet fully understood. Recent preclinical studies and clinical evidence indicate that changes in the gut microbiome could potentially play a role in the accumulation of amyloid beta. However, the relationship between gut dysbiosis and AD is still elusive. In this review, the potential impact of the gut microbiome on AD development and progression is discussed. Pre-clinical and clinical literature exploring changes in gut microbiome composition is assessed, which can contribute to AD pathology including increased amyloid beta deposition and cognitive impairment. The gut-brain axis and the potential involvement of metabolites produced by the gut microbiome in AD are also highlighted. Furthermore, the potential of antibiotics, prebiotics, probiotics, fecal microbiota transplantation, and dietary interventions as complementary therapies for the management of AD is summarized. This review provides valuable insights into potential therapeutic strategies to modulate the gut microbiome in AD.
阿尔茨海默病（AD）是最常见的痴呆类型，但它的病因发病机制尚未完全阐明。最近的临床前研究和临床证据表明，肠道微生物组的变化可能在β淀粉样蛋白的积累中发挥作用。然而，肠道菌群失调与 AD 之间的关系仍不清楚。在这篇综述中，讨论了肠道微生物组对 AD 发展和进展的潜在影响。评估了探索肠道微生物组组成变化的临床前和临床文献，这些变化可能导致 AD 病理，包括增加β淀粉样蛋白沉积和认知障碍。还强调了肠道-大脑轴以及肠道微生物组产生的代谢物在 AD 中的潜在作用。此外，还总结了抗生素、益生元、益生菌、粪便微生物移植和饮食干预作为 AD 管理的补充疗法的潜力。本综述为调节 AD 肠道微生物组的潜在治疗策略提供了有价值的见解。
